On December 7th 2025, at the American Society of Hematology (ASH) Annual Meeting, Jan Geissler presented the CML Advocates Network–led poster titled “Patient Preferences in CML Treatment.” This important study reflects months of collaboration, outreach, and support from our global community of CML patient organisations, who played a key role in promoting the survey and helping us reach a diverse group of participants. We extend our sincere thanks to everyone involved.
About the Study
This multi-country patient preference study aims to better understand which treatment attributes matter most to people living with Chronic Myeloid Leukemia. The insights gained can help guide healthcare professionals, researchers, and decision-makers toward more patient-centred approaches in future treatment development.
Key Finding: Fatigue as a Critical Burden
Among all the insights collected, one finding clearly stood out:
Fatigue continues to be one of the most significant and burdensome symptoms for people with CML.
Patients reported that fatigue strongly affects their daily life, and it plays a major role in shaping their treatment preferences and priorities.
These insights underline the need for ongoing efforts to improve symptom management and incorporate patient-reported outcomes into clinical decision-making.
Next Steps
The manuscript for this study is currently in the final stages of development. We will share it as soon as it becomes available.
